AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02489383 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Program
Description: The education program will discuss issues related to asthma and physical activity. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peak flow meter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
Study NCT02153580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Description: Given IV
Study NCT02153580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV
Study NCT02153580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02153580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02153580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02139488 — intervention group
Intervention type: OTHER
Intervention: Fiducial markers
Study NCT02139488 — intervention group
Intervention type: OTHER
Intervention: Fiducial markers, Pet and MRI
Description: Insertion of Fiducial markers in esophageal wall.
Study NCT02059304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of cervical length with embryo transfer catheter
Study NCT01934010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-101
Description: AM-101 gel for intratympanic injection
Study NCT01497301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Visits
Description: During group visits, there will be discussions regarding the basic pathophysiology of diabetes, the ABCs to Better Diabetic Care as defined by the ACP Diabetes Care Guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. Patients will have blood drawn to measure hemoglobin A1C and lipids. They will be educated on self glucose monitoring so they will undergo finger sticks to measure their own glucose. BP measurements, monofilament foot exams, and urine collection for microalbumin will also occur during the study. They may also receive immunizations. A consent form for participation in the group visits, including undergoing the above procedures will be reviewed at our first group visit and signed by all participants.
Study NCT03515096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.
Study NCT03515096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rhTPO
Description: rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.
Study NCT01733394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine
Study NCT02874755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuberculosis Program
Description: The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free digital chest X-ray, free sputum microscopy, free or subsidized drug-susceptibility testing, free first-line anti-TB treatment) within the PPIA network, and (2) training or certified medical education (CME) sessions for the providers from the PPIA. Meanwhile, program marketing, CMEs, and other advocacy efforts are aimed to raise awareness in the communities.
Study NCT01620814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Study NCT01620814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Study NCT01620814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control
Study NCT03369769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity
Description: 10 minutes interaction with therapy dog and adult handler in small group (2-4 participants).
Study NCT03369769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity
Description: 10 minutes interaction with therapy dog and adult handler in small group (2-4 participants).
Study NCT01095302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMBRABULIN (AVE8062)
Description: Pharmaceutical form:injection solution~Route of administration: intravenous infusion
Study NCT01095302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Pharmaceutical form:injection solution~Route of administration: intravenous infusion
Study NCT01095302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Pharmaceutical form:injection solution~Route of administration: intravenous infusion
Study NCT03719911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live diabetes coaching program
Description: Live diabetes coaching program
Study NCT01035281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone, flexible dosing
Description: nabilone at 0.5 - 4 mg/day
Study NCT01035281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nabilone, flexible dosing
Description: nabilone at 0.5 - 4 mg/day
Study NCT00410007 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: High Sodium Diet
Description: 250-350 mmol
Study NCT00410007 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Sodium Diet
Description: 25-35 mmol
Study NCT00410007 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hypertonic saline infusion
Description: 7 ml/ kg of 3% saline were given over 30 minutes.
Study NCT04102072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trendelenburg Maneuver
Description: In the Trendelenburg position, the body is laid supine with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
Study NCT01559142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab with azathioprine (IIFX + AZA)
Description: Infliximab with azathioprine during whole one year study
Study NCT01559142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab (IFX alone)
Description: Infliximab continuously; azathioprine stopped in 26 week
Study NCT03554798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nOPV2 (monovalent oral polio vaccine)
Description: Cohort A: 150 IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1 or 2; two 10‸6 CCID50 (50% cell culture infective dose) doses separated by 28 days.~Cohort B: 972 infants enrolled at 6 weeks of age (-7 to +14 days) vaccinated with 3 doses of bOPV at 6, 10 and 14 weeks of age and 1 dose of IPV at 14 weeks of age, followed at 18-22 weeks of age with one 10‸5 CCID50 dose of candidate 1 or 2.
Study NCT03487562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 Amg
Description: DWP14012 Amg
Study NCT03487562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 Bmg
Description: DWP14012 Bmg
Study NCT03487562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg
Study NCT00408525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.
Study NCT04102072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dobutamine stress test
Description: Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. Echocardiography was performed after 5-10 minutes of continuous infusion, and hemodynamic data were recorded.
Study NCT01947751 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVC exchange
Description: CVC exchange when related infection is suspected
Study NCT01947751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVC maintenance
Description: CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
Study NCT03815461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and S-1
Description: Nab-paclitaxel was administered at 125mg/m2 intravenously on day 1 and 8, S-1 （80, 100, or 120 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle for 4-6 cycles.
Study NCT02732834 — intervention group
Intervention type: BEHAVIORAL
Intervention: 2-hour empathic communication skills training
Description: 2-hour empathic communication skills training
Study NCT02732834 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standardized Patient Assessments
Description: pre-training SPA, post-training SPA
Study NCT02732834 — intervention group
Intervention type: BEHAVIORAL
Intervention: Training evaluation
Description: Clinicians will complete an evaluation assessing the empathic communication training module.
Study NCT02278861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral isotretinoin
Description: Oral isotretinoin - 10mg/day (one pill) after lunch for six months
Study NCT02278861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin 0,05% cream
Description: Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
Study NCT02278861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen FPS 60
Description: Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
Study NCT04060056 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized breakfast
Description: Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
Study NCT04060056 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized snack
Description: Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
Study NCT04060056 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized lunch
Description: Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
Study NCT02112851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Orange flavored beverage
Description: Intervention involves consumption of one beverage of 240ml following baseline measurements
Study NCT02112851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange flavored beverage
Description: Intervention involves consumption of one beverage of 240ml following baseline measurements
Study NCT03371784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: I.V. administration
Study NCT03346096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: fixed dose 5mg/kg on days -7-6
Study NCT01313377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT01313377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT01313377 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: clinical observation
Study NCT01313377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT01313377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT01313377 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: quality-of-life assessment
Study NCT03371784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.V. administration
Study NCT00517361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 6 in 250mL saline IV over 30 minutes
Study NCT00517361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15mg/kg in 100mL saline IV over 60 - 90 minutes
Study NCT03631758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-based information
Description: Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
Study NCT03631758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: Patient Decision Aid for breast cancer screening decision
Study NCT03631758 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham information
Description: Educational information not specific to mammography or cancer screening
Study NCT03549377 — intervention group
Intervention type: BEHAVIORAL
Intervention: Deception
Description: Participants will be deceived during delayed gratification task.
Study NCT01289678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days
Study NCT03487562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 1 g
Study NCT02574182 — intervention group
Intervention type: RADIATION
Intervention: Brain MRI
Description: Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters
Study NCT03927144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG334
Description: Subcutaneous Injection
Study NCT04768192 — intervention group
Intervention type: PROCEDURE
Intervention: Physical Rehabilitation without lokomat
Description: Conventional physiotherapy is performed in 10 weekly sessions (45 minutes each) over 4 weeks(total 40 sessions).~Specific exercises are administered to improve gait, balance and functional abilities focusing on:~strengthening the gluteus and quadriceps muscles stretching the hip flexor and hamstrings muscles increasing static balance increasing dynamic balance increasing functional abilities improving ground gait going up and down the stairs.~Physiotherapists can choose from a list of 25 standard exercises, according to some constraints:~1. strengthening exercises had to involve all the lower limb joints (no segmental intervention)~2. during each session, at least 4 out of the 7 categories above had to be delivered~3. the impossibility to perform any of the categories above during any session had to be recorded in the patient's treatment diary.~Physiotherapists of the treatments group discuss patients' diaries during weekly meetings.
Study NCT03927144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG334
Description: Subcutaneous Injection
Study NCT03927144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Prophylactic
Description: SOC Oral Tablet/Capsule
Study NCT03927144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Prophylactic
Description: SOC Oral Tablet/Capsule
Study NCT02732834 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient recruitment
Description: 6 of the clinician's patients (3 pre-training, 3 post-training) will be recruited to complete brief surveys assessing clinician communication
Study NCT04445558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplementation
Description: Adjunction of oral nutritional supplementation
Study NCT04445558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: intradialytic parenteral nutrition
Description: Adjunction of intradialytic parenteral nutrition
Study NCT02985632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141
Study NCT01301872 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: check biomarker :RAGE
Description: We will check RAGE for all patients who have ARDS included in our study
Study NCT01166685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Description: Everolimus-eluting stent
Study NCT04768192 — intervention group
Intervention type: PROCEDURE
Intervention: Physical Rehabilitation with Lokomat
Description: The rehabilitation protocol consists of 20 sessions of robotic training alternated with 20 sessions of conventional physiotherapy (CP). Each treatment is performed in 5 weekly sessions (45 minutes each) over 4 weeks.~Robotic training aimed to recovery/improve walking capacity from the initial Gross Motor Function Classification System (GMFCS) level. It is performed using the Lokomat® (Hocoma AG, Volketswil, Switzerland) gait orthosis. Initial set ups includes 50% body weight unload, gait velocity adjusted on the patient individual capability (1.5 km/h on average) and 100% guidance force. Both weight unload and guidance force are gradually reduced across sessions according to patient recovery of muscle strength and allowing patients to work harden and move more freely.~Children engagement, active participation and motivation were reinforced through frequent encouragement by therapists and performance feedback implemented in the exercise video-games.
Study NCT01090414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablets or capsules administered orally
Study NCT04575610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric \[NG\] tube, orogastric \[OG\] tube, or equivalent) if unable to take tablets by mouth (PO). Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD). Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD. All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
Study NCT04575610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets will be administered.
Study NCT01597310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: single doses at specified time periods
Study NCT01597310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: multiple doses
Study NCT00138008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endocrine therapy
Description: Drug: endocrine therapy
Study NCT00138008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Procedure/Surgery: radiotherapy
Study NCT01288079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet, oral, twice daily for 8 weeks
Study NCT01288079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Capsule, oral, once daily
Study NCT01288079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral, twice daily for 8 weeks
Study NCT01111318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: 2 tablets BI 10773 25 mg single dose
Study NCT01295320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample will be collected at Month 48, Month 60 and Month 72
Study NCT01166685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare-metal stent
Description: Bare metal stent
Study NCT01204021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih
Description: 12 weeks of weekly classes of Tai Chi Chih
Study NCT01204021 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Education Control
Description: Weekly meetings, for 2 hours for 12 weeks discussing issues related to stress education.
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 Mg capsules of bosutinib in Water solution
Description: 200 mg (4X50) Capsules in water
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosunitib sorbitol
Description: 200 Mg of bosutinib sorbitol solution
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib Mannitol
Description: Bosutinib mannitol solution
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib in mannitol low sweet
Description: bosutinib in mannitol solution low sweet
Study NCT01166685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable Polymer-DES
Description: drug-eluting stent with bioabsorbable polymer
Study NCT01246947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tricuspid valve repair
Description: Randomized to receive Tricuspid valve repair using a rigid 3-dimensional annuloplasty ring using standard techniques, during Mitral surgery.
Study NCT01246947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mitral surgery alone
Description: Randomized to Mitral surgery alone
Study NCT03487562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30 mg